MX2023006483A - Terapia radionuclidica de receptores peptidicos. - Google Patents
Terapia radionuclidica de receptores peptidicos.Info
- Publication number
- MX2023006483A MX2023006483A MX2023006483A MX2023006483A MX2023006483A MX 2023006483 A MX2023006483 A MX 2023006483A MX 2023006483 A MX2023006483 A MX 2023006483A MX 2023006483 A MX2023006483 A MX 2023006483A MX 2023006483 A MX2023006483 A MX 2023006483A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- peptide receptor
- radionuclide therapy
- receptor radionuclide
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121762P | 2020-12-04 | 2020-12-04 | |
| PCT/US2021/061886 WO2022120226A1 (en) | 2020-12-04 | 2021-12-03 | Peptide receptor radionuclide therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006483A true MX2023006483A (es) | 2023-07-20 |
Family
ID=81853616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006483A MX2023006483A (es) | 2020-12-04 | 2021-12-03 | Terapia radionuclidica de receptores peptidicos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240131206A1 (https=) |
| EP (1) | EP4255891A4 (https=) |
| JP (1) | JP2023552383A (https=) |
| KR (1) | KR20230117581A (https=) |
| CN (1) | CN116829541A (https=) |
| AU (1) | AU2021390552A1 (https=) |
| CA (1) | CA3203175A1 (https=) |
| MX (1) | MX2023006483A (https=) |
| WO (1) | WO2022120226A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025160502A1 (en) | 2024-01-26 | 2025-07-31 | The Regents Of The University Of California | Peptide receptor radionuclide therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0282057A3 (en) * | 1987-03-11 | 1990-03-07 | The Board Of Regents Of The University Of Michigan | Chemo-radio-immuno-conjugates |
| MX340566B (es) * | 2007-03-27 | 2016-07-14 | Radiomedix Inc | Composiciones para formacion de imagen objetivo y terapia. |
| US20120015899A1 (en) * | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
| WO2011082191A1 (en) * | 2009-12-30 | 2011-07-07 | Ge Healthcare Limited | Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning |
| CA2945945C (en) * | 2014-04-15 | 2023-10-03 | The Regents Of The University Of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
| EP3468984A4 (en) * | 2016-06-13 | 2020-03-11 | The Regents of the University of California | ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF |
| MX2019005742A (es) * | 2016-11-23 | 2019-09-13 | Cancer Targeted Tech Llc | Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina. |
| GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
| CN111032632B (zh) * | 2017-05-30 | 2024-04-12 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| CN109091683B (zh) * | 2018-08-10 | 2019-10-18 | 北京大学 | 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法 |
| WO2021226432A2 (en) * | 2020-05-08 | 2021-11-11 | The Regents Of The University Of California | Methods of detecting and treating lung damage in respiratory-related viral infections |
-
2021
- 2021-12-03 AU AU2021390552A patent/AU2021390552A1/en active Pending
- 2021-12-03 WO PCT/US2021/061886 patent/WO2022120226A1/en not_active Ceased
- 2021-12-03 US US18/038,851 patent/US20240131206A1/en active Pending
- 2021-12-03 MX MX2023006483A patent/MX2023006483A/es unknown
- 2021-12-03 JP JP2023533889A patent/JP2023552383A/ja active Pending
- 2021-12-03 KR KR1020237020941A patent/KR20230117581A/ko active Pending
- 2021-12-03 EP EP21901568.2A patent/EP4255891A4/en active Pending
- 2021-12-03 CN CN202180092891.6A patent/CN116829541A/zh active Pending
- 2021-12-03 CA CA3203175A patent/CA3203175A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022120226A1 (en) | 2022-06-09 |
| CN116829541A (zh) | 2023-09-29 |
| EP4255891A4 (en) | 2026-03-18 |
| AU2021390552A9 (en) | 2024-06-20 |
| AU2021390552A1 (en) | 2023-06-29 |
| CA3203175A1 (en) | 2022-06-09 |
| US20240131206A1 (en) | 2024-04-25 |
| JP2023552383A (ja) | 2023-12-15 |
| EP4255891A1 (en) | 2023-10-11 |
| KR20230117581A (ko) | 2023-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL163573A0 (en) | Conjugates of therapeutic or cytotoxic agents and biologically active peptides | |
| TR200103337T2 (tr) | Protez inhibitrleri olarak yeni bileçikler ve bileçimler | |
| SV1998000122A (es) | Medicamentos ref. pu 3375/sv | |
| DE69812159D1 (de) | Derivate des adamantan | |
| BR0314356A (pt) | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| PT1093819E (pt) | Compostos e composicoes para fornecimento de agentes activos | |
| IL175158A0 (en) | Tocopherol-modified therapeutic drug compounds | |
| ATE514418T1 (de) | Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan | |
| TR199901417T2 (xx) | Analjezik etkisi olan yeni bile�imler. | |
| AU2002359727A8 (en) | Fused cyclic modulators of nuclear hormone receptor function | |
| SE9301667D0 (sv) | New use | |
| AU5338401A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| DE60040753D1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
| BR0111869A (pt) | Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear | |
| NO20004419D0 (no) | Ny anvendelse | |
| DE69836582D1 (de) | Kurze peptide die die aktivität serine/threonine kinasen modulieren | |
| MX2023006483A (es) | Terapia radionuclidica de receptores peptidicos. | |
| TR200200359T2 (tr) | Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması | |
| MX2010000997A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b). | |
| CY1105211T1 (el) | Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη | |
| FR12C0064I2 (fr) | Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale | |
| AU2003256882A8 (en) | Methods of drug delivery using sulphated chitinous polymers | |
| TR200202702T2 (tr) | Nükleer hormon reseptör fomksiyonun kaynaşmış halkalı modülatörleri. | |
| ECSP992866A (es) | Derivados de sulfonamida |